[go: up one dir, main page]

PE20040516A1 - Derivados de 1,2-azol - Google Patents

Derivados de 1,2-azol

Info

Publication number
PE20040516A1
PE20040516A1 PE2003000503A PE2003000503A PE20040516A1 PE 20040516 A1 PE20040516 A1 PE 20040516A1 PE 2003000503 A PE2003000503 A PE 2003000503A PE 2003000503 A PE2003000503 A PE 2003000503A PE 20040516 A1 PE20040516 A1 PE 20040516A1
Authority
PE
Peru
Prior art keywords
pirazo
etoxy
lil
substitutes
trifluoromethyl
Prior art date
Application number
PE2003000503A
Other languages
English (en)
Inventor
Kohji Fukatsu
Ryoma Hara
Hiroyuki Odaka
Tsuyoshi Maekawa
Hideya Mizufune
Hiroyuki Kimura
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PE20040516A1 publication Critical patent/PE20040516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES UN ANILLO CON 1 A 3 TRES SUSTITUYENTES; B ES UN ANILLO 1,2- AZOL CON 1 A 3 SUSTITUYENTES; Xa, Xb Y Xc SON CADA UNO UN ENLACE, -O-, -S-, -SO-, -CS-, ENTRE OTROS; Ya ES RESIDUO DE HIDROCARBURO ALIFATICO DIVALENTE CON 1 A 20 ATOMOS DE CARBONO; Yb E Yc SON CADA UNO UN ENLACE O RESIDUO DE HIDROCARBURO ALIFATICO DIVALENTE CON 1 A 20 ATOMOS DE CARBONO; C ES ANILLO AROMATICO MONOCICLICO CON 1 A 3 SUSTITUYENTES; R ES -OR4, -NR5R6; R4 ES H, HIDROCARBURO; R5 Y R6 SON CADA UNO H, HIDROCARBURO Y GRUPO HETEROCICLICO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 3-[1-FENIL-3-(4-{3-[4-(TRIFLUOROMETIL)FENIL]-5-ISOXAZOLIL}BUTOXI-1H-PIRAZO-5-LIL]PROPIONICO; ACIDO 2-[3-(3-{3-ETOXI-1-[5-(TRIFLUOROMETIL)-2-PIRIDIL]-1H-PIRAZO-4-LIL}PROPOXI)FENOXI]-2-METILPROPIONICO Y ACIDO 3-[2-ETOXI-4-(3-{3-ETOXI-1-[5-(TRIFLUOROMETIL)-2-PIRIDIL]-1H-PIRAZO-4-LIL}PROPOXI)FENIL]PROPIONICO. SE REFIERE TAMBIEN A UN METODO DE PRODUCCION DE DICHOS COMPUESTOS QUE SON UTILES PARA PROFILAXIS O TRATAMIENTO DE DIABETES, HIPERLIPIDEMIA, ARTERIOESCLEROSIS, TOLERANCIA PERJUDICIAL A LA GLUCOSA Y SIMILARES
PE2003000503A 2002-05-24 2003-05-23 Derivados de 1,2-azol PE20040516A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002151405 2002-05-24
JP2002287161 2002-09-30
JP2003016748 2003-01-24

Publications (1)

Publication Number Publication Date
PE20040516A1 true PE20040516A1 (es) 2004-10-01

Family

ID=29587460

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000503A PE20040516A1 (es) 2002-05-24 2003-05-23 Derivados de 1,2-azol

Country Status (8)

Country Link
US (1) US20060148858A1 (es)
EP (1) EP1513817A1 (es)
AR (1) AR040043A1 (es)
AU (1) AU2003241173A1 (es)
CA (1) CA2487315A1 (es)
PE (1) PE20040516A1 (es)
TW (1) TW200407309A (es)
WO (1) WO2003099793A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR041867A1 (es) 2002-11-01 2005-06-01 Takeda Pharmaceutical Agente para prevenir o tratar neuropatia
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US20060241157A1 (en) * 2003-01-06 2006-10-26 Conner Scott E Heterocyclic ppar modulators
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315569A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315573A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
WO2005011677A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ATE361294T1 (de) * 2003-08-20 2007-05-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
US8008525B2 (en) 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
AU2005219536A1 (en) * 2004-03-09 2005-09-15 F. Hoffmann-La Roche Ag Pyrazolyl indolyl derivatives as PPAR activators
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2005099759A1 (ja) * 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. 動脈硬化症の予防及び／又は治療のための医薬
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US20080045580A1 (en) * 2004-10-11 2008-02-21 Dr Reddy's Laboratories Limited Novel Isoxazole Compounds Having Ppar Agonist Activity
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7767827B2 (en) 2005-05-23 2010-08-03 Kaken Pharmaceutical Co., Ltd. Pyrazole-1-carboxylate derivatives, process for the production thereof and process for the production of pyrazole derivatives
WO2006126514A1 (ja) 2005-05-27 2006-11-30 Shionogi & Co., Ltd. イソキサゾール骨格を有するアリール酢酸誘導体
BRPI0615948A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc composto ativo de ppar, sua composição, seu kit e seu uso
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
ZA200809148B (en) 2006-04-18 2010-01-27 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta
EP2043970B1 (en) * 2006-07-05 2018-04-18 Centre National De La Recherche Scientifique (C.N.R.S.) Iron-copper co-catalyzed process for carbon-carbon or carbon-heteroatom bonding
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
WO2008093639A1 (ja) * 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) * 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
AU2008333326B2 (en) 2007-12-04 2013-05-30 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
US8436043B2 (en) 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2260017A1 (en) 2008-03-06 2010-12-15 Amgen, Inc Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009236877B2 (en) 2008-04-15 2014-01-23 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
CA2739888C (en) 2008-10-15 2013-11-19 Amgen Inc. Spirocyclic gpr40 modulators
CN102186825A (zh) * 2008-10-21 2011-09-14 麦它波莱克斯股份有限公司 芳基gpr120受体激动剂和其用途
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2897953B8 (en) * 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
US9133163B2 (en) 2012-11-16 2015-09-15 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MY199131A (en) 2014-03-07 2023-10-17 Biocryst Pharm Inc Human plasma kallikrein inhibitors
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110143910B (zh) * 2019-06-03 2022-04-05 华侨大学 一种多取代吡咯烷酮衍生物的制备方法
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
DE3836581A1 (de) * 1988-10-27 1990-05-03 Basf Ag Heterocyclisch substituierte (alpha)-aryl-acrylsaeuremethylester und ihre verwendung
US5166216A (en) * 1988-10-27 1992-11-24 Basf Aktiengesellschaft Methyl α-arylacrylates substituted by a heterocyclic radical and their use
ATE121080T1 (de) * 1989-12-13 1995-04-15 Mitsubishi Chem Corp Pyrazolylacrylsäure-derivate, verwendbar als systemische fungiziden in pflanzen- und materialschutz.
US4956376A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Tetrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2036192A1 (en) * 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US5236938A (en) * 1991-04-30 1993-08-17 Rhone-Poulenc Inc. Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles
DE4116090A1 (de) * 1991-05-17 1992-11-19 Basf Ag (alpha)-phenylacrylsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen und schadpilzen
DE4117371A1 (de) * 1991-05-28 1992-12-03 Basf Ag Antimykotische mittel, die phenylessigsaeurederivate enthalten
DE4124989A1 (de) * 1991-07-27 1993-02-04 Basf Ag (beta)-substituierte zimtsaeurederivate
DE4126994A1 (de) * 1991-08-16 1993-02-18 Basf Ag (alpha)-arylacrylsaeurederivate, ihre herstellung und verwendung zur bekaempfung von schaedlingen und pilzen
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
EP0581095A2 (de) * 1992-07-24 1994-02-02 BASF Aktiengesellschaft Substituierte Acrylsäureester und diese enthaltende Pflanzenschutzmittel
DE4305502A1 (de) * 1993-02-23 1994-08-25 Basf Ag Ortho-substituierte 2-Methoxyiminophenylessigsäuremethylamide
DE4338104A1 (de) * 1993-11-08 1995-05-11 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
KR970006238B1 (en) * 1994-03-15 1997-04-25 Korea Res Inst Chem Tech Propenoic ester derivatives having 4-hydroxy pyrazole group
IL113414A (en) * 1994-05-03 2000-08-13 Basf Ag Substituted methyl alpha-phenylbutenoates their preparation and use for combating harmful fungi and animal pests
ATE184276T1 (de) * 1994-07-06 1999-09-15 Basf Ag Pyrazolylderivate, ihre herstellung und ihre verwendung als schädlingsbekämpfungsmittel
IL118054A0 (en) * 1995-05-09 1996-08-04 Basf Ag (Het) aryloxy-,(-thio- and -amino-)-crotonates their preparation and pharmaceutical compositions containing them
DE19519041A1 (de) * 1995-05-24 1996-11-28 Basf Ag Azolyloxybenzyl-alkoxyacrylsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2740135B1 (fr) * 1995-10-20 1997-12-19 Roussel Uclaf Nouveaux derives de pyrazoles acides, leur procede de preparation, leur application a titre de medicaments, leur nouvelle utilisation et les compositions pharmaceutiques les renfermant
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
ZA981934B (en) * 1997-03-10 1999-09-06 Rhone Poulenc Agrochimie Pesticidal 1-aryl-3-iminopyrazoles.
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
KR100512227B1 (ko) * 1997-09-05 2005-09-05 바스프 악티엔게젤샤프트 헤테로(방향족)히드록실아민의 제조 방법
US6080839A (en) * 1998-06-25 2000-06-27 Wallac Oy Labeling reactants and their use
DE60027420T2 (de) * 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP3723071B2 (ja) * 1999-11-10 2005-12-07 武田薬品工業株式会社 含窒素５員複素環化合物
DE60131967D1 (de) * 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen

Also Published As

Publication number Publication date
TW200407309A (en) 2004-05-16
CA2487315A1 (en) 2003-12-04
AU2003241173A1 (en) 2003-12-12
WO2003099793A8 (en) 2004-12-29
US20060148858A1 (en) 2006-07-06
EP1513817A1 (en) 2005-03-16
AR040043A1 (es) 2005-03-09
WO2003099793A9 (en) 2005-02-10
AU2003241173A8 (en) 2003-12-12
WO2003099793A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
PE20040516A1 (es) Derivados de 1,2-azol
PE20001562A1 (es) Derivados de benzamida como inhibidores de la produccion hepatica de la apo proteina b-100
PE20000947A1 (es) ACTIVADORES DE hPPARþ Y hPPARO
PE20060825A1 (es) Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE20050147A1 (es) Derivados de pirimidina, piridina y tiazol como inhibidores de fosfatidilinositol 3-quinasa
PE20080259A1 (es) Compuestos y metodos para modular fxr
PE20051146A1 (es) Compuestos heterociclicos anticitocina
JP2002520309A5 (es)
PE20050444A1 (es) Compuestos de piridina como inhibidores de la peptidasa
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
PE20060417A1 (es) Indazoles como moduladores de lxrs
AU5257401A (en) Novel bicyclic compounds
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
MY176115A (en) Method for preparing 5-haloalkyl-4, 5-dihydroisoxazole derivatives
JP2008505874A5 (es)
PE20051159A1 (es) Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina
PE20011010A1 (es) Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
FI884350A0 (fi) Som antagonister nyttiga nya benzimidazolin-2-oxo-1-karboxylsyraderivat av 5-ht reseptor.
ATE368653T1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20050079A1 (es) Derivados de pirrolidona como inhibidores de maob
NO20074055L (no) Prosesser for a fremstille 4-(fenoksy-5-metylpyrimidin-4-yloksy)piperidin-1-karboksylsyrederivater og relaterte forbindelser
PE20091930A1 (es) Compuestos de pirazol, procesos para su produccion y herbicidas que los contienen
PE20030930A1 (es) Derivados de tiazol como antagonistas del receptor npy
PE20030763A1 (es) Inhibidores de la integrasa del vih

Legal Events

Date Code Title Description
FC Refusal